Clinical trial · Interventional
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
AN OPEN LABEL, SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024 (APC8015F) FOR MEN WITH OBJECTIVE DISEASE PROGRESSION ON PROTOCOL D9902 PART B
NCT00849290CI-TRIAL-00071807completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Androgen Independent Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| APC8015F | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- APC8015F
- interventionNames
- Biological: APC8015F
Primary outcomes (1)
- measure
- Safety of APC8015F by Review of Reported Adverse Events
- timeFrame
- periodically over 24 months
- description
- All subjects who received at least one infusion of APC8015F (N = 109) were included in the safety analysis set and were followed for safety. Refer to Serious Adverse Events and Other Adverse Events.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Objective disease progression * Subjects must have been enrolled in the APC-Placebo arm of D9902B (NCT00065442) Exclusion Criteria: * Infection requiring IV antibiotics * Treatment with anticancer interventions within 14 days prior to enrollment * Any medical condition which could compromise the study's objectives (discretion from sponsor)
References
Publications (0)
Data not yet available
No reference posted for this study.